BioSpace News Archive

The U.S. FDA approval of EPKINLY as the first bispecific antibody to treat adults with relapsed or refractory DLBCL was an important milestone both for Genmab and for patients in need of an innovative treatment option administered subcutaneously.

Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report financial results and provide business updates for the second quarter ended June 30, 2023, before the US markets open on Wednesday, August 9, 2023. Following the announcement, the Company will host a live conference call at 8:00 a.m. EDT (1:00 p.m. BST) that same day.

TrialAssure, a leading software-as-a-service (SaaS) provider advancing clinical trial disclosure, data sharing, and transparency, announced today that it is collaborating with MMS, a global clinical research organization, on a new artificial intelligence (AI) initiative aimed at developing generative text specifically for medical writing in the field of drug development.

Kura Oncology, Inc. reported second quarter 2023 financial results and provided a corporate update.

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today announced financial results for the second quarter ended June 30, 2023, and highlighted recent Company progress.

Collegium Pharmaceutical, Inc., a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, reported its financial results for the quarter ended June 30, 2023, and provided a corporate update.

Inozyme Pharma, Inc. announced that the Company granted stock options to new employees to purchase shares of the Company’s common stock, pursuant to the Company’s 2023 Inducement Stock Incentive Plan, each as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635.

Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the second quarter 2023 on Tuesday, August 8, 2023, after market close.

The Access to Advanced Health Institute announced that it has received an $18 million award from the National Institutes of Health to develop a temperature stable, single-dose vaccine candidate for the chikungunya virus.

CNS Pharmaceuticals, Inc. today announced that John Climaco, CEO of CNS Pharmaceuticals will participate in a fireside chat at Benzinga’s Virtual Biotech Conference.